2 of 3 products has already been commercialized (RAP just need to get the ResAppDx's Android version for telehealth completed and create a robust and "quick" benchmark testing which they did for iPhone) so less resource will be need for the acute respiratory diagnosis and OSA, chronic respiratory management which hasn't been yet commercialize use similar technology to ResAppDx so they will be able to extend the process to this so I don't expect much resource will be need for once this product reach the market. But there might be 4 products with massive revenue potential instead of 3 by this time next year......
- Forums
- ASX - By Stock
- RAP
- Ann: AstraZeneca to use new ResApp software in clinical study
Ann: AstraZeneca to use new ResApp software in clinical study, page-41
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online